Company Overview and News
New Zealand shares fell the most across Asia as Z Energy led the market lower for another day amid rising oil prices, growing competition and the threat of increased regulation.
CEN PGC AIR FCREY ZNRGF NZTCF RYM ACKDF ANZFY AUKNY AIZ COENF SKT ZNZ SYKWF CEN SKKTY AIA FBU RHCGF SPKKY NZTCY EBOSY SPK ZEL FRCEF EBO COENY KWIPF EBOSF AIA FBU ANZLY RYHTY ANZFF MEZ EBO
Genesis has labelled Meridian's statements regarding prompt payment discounts ''unhelpful'', in a sign of intense pressure felt by power companies facing a pricing review and locked in a heated battle for customers.
CEN COENF GNE CEN GNE MEZ COENY GEL
New Zealand shares fell for a fourth day as A2 Milk Co remains out of favour after recent selling by its chief executive and a director. Genesis Energy and Auckland International Airport also declined after shedding rights to dividend payments.
CEN AIA FBU RHCGF FCREY CMO RYM ACKDF FRCEF AUKNY COENY KWIPF COENF GNE AIA PPSHY FBU RYHTY CEN GNE MEZ GEL
New Zealand shares edged higher as improved confidence lifted building and tourism stocks. Rising oil prices kept investors nervous about higher energy costs for companies, and was identified as a headwind for Air New Zealand at its annual meeting.
CEN PYIYY AIR FCREY ZNRGF ACKDF ANZFY AUKNY AIZ COENF ZNZ CEN SML AIA FBU ZEL FRCEF COENY KWIPF AIA FBU THL ANZLY ANZFF MEZ PFI
New Zealand shares edged higher as investors wait for the upcoming round of annual meetings for a clearer steer on company outlooks.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ COENF SKT SYKWF CEN SKKTY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY OHE ANZFF MEZ
New Zealand shares edged higher as Tourism Holdings snapped a seven-day slide on a broker upgrade. Spark New Zealand was among several companies shedding rights to dividends.
CEN BGR FBU AIR FCREY SPKKY NZTCY SPK NZTCF FRCEF ANZFY COENY AIZ COENF GNE FBU THL ANZLY CEN ANZFF GNE MEZ GEL
Meridian Energy has axed "unjustifiable" prompt payment discounts, effectively cutting its power prices to all customers by the 10-to-16 per cent discount it has traditionally offered to those who pay their electricity bills on time.
CEN COENF CEN MEZ COENY
New Zealand shares rose, joining a regional rally on optimism over US-China trade relations. Fonterra Cooperative Group's first annual loss dominated local headlines.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF GNE CEN KMD GEL SML KTHDY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY ANZFF GNE MEZ
New Zealand shares rose as investors weigh up the prospect of a potential rate cut, spurring demand for stocks with high dividends, in a world economy that remains relatively robust. Sky Network Television, Spark New Zealand and Chorus gained.
KTHDY CEN PGC SPKKY NZTCY SPK NZTCF COENY KMD COENF SKT SYKWF CEN SKKTY KMD
New Zealand shares surged to a record as the market reopened after yesterday's platform failure. Synlait Milk and A2 Milk Co led the gains.
CEN FBU WBC FCREY ZNRGF WEBNF WBK FRCEF ZEL COENY COENF SKT ZNZ GNE SYKWF WBC FBU CEN SNZ SKKTY GNE GEL SML
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET